SNY Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of 36.7% compared to Sanofi's net margin of --. Sanofi's return on equity of 12.45% beat DBV Technologies SA's return on equity of -280.59%.

Sanofi has a consensus price target of $59.35, signalling upside risk potential of 22.45%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 107.86%. Given that DBV Technologies SA has higher upside potential than Sanofi, analysts believe DBV Technologies SA is more attractive than Sanofi.

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.53%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than DBV Technologies SA quarterly revenues of --. Sanofi's net income of $4.5B is higher than DBV Technologies SA's net income of -$33M. Notably, Sanofi's price-to-earnings ratio is 12.10x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.79x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -19.69%. Sanofi's return on equity of 12.45% beat Moderna, Inc.'s return on equity of -30.18%.

Sanofi has a consensus price target of $59.35, signalling upside risk potential of 22.45%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 17.79%. Given that Sanofi has higher upside potential than Moderna, Inc., analysts believe Sanofi is more attractive than Moderna, Inc..

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.53%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Moderna, Inc. quarterly revenues of $1B. Sanofi's net income of $4.5B is higher than Moderna, Inc.'s net income of -$200M. Notably, Sanofi's price-to-earnings ratio is 12.10x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.79x versus 5.41x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -287.29%. Sanofi's return on equity of 12.45% beat Novavax, Inc.'s return on equity of --.

Sanofi has a consensus price target of $59.35, signalling upside risk potential of 22.45%. On the other hand Novavax, Inc. has an analysts' consensus of $12.78 which suggests that it could grow by 87.08%. Given that Novavax, Inc. has higher upside potential than Sanofi, analysts believe Novavax, Inc. is more attractive than Sanofi.

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.53%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Novavax, Inc. quarterly revenues of $70.4M. Sanofi's net income of $4.5B is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Sanofi's price-to-earnings ratio is 12.10x while Novavax, Inc.'s PE ratio is 3.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.79x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 36.7% compared to Sanofi's net margin of 38.89%. Sanofi's return on equity of 12.45% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Sanofi has a consensus price target of $59.35, signalling upside risk potential of 22.45%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $795.38 which suggests that it could grow by 1.33%. Given that Sanofi has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Sanofi is more attractive than Regeneron Pharmaceuticals, Inc..

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.53%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Sanofi pays 66.53% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Sanofi's net income of $4.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Sanofi's price-to-earnings ratio is 12.10x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.79x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.